Sunday, 22 December 2024
  
Login

Australia's most trusted
source of pharma news

Sunday, 22 December 2024
News

Slow-burning blockbuster tops PBS

Posted 26 July 2024 AM

It took longer than expected, but MSD's monoclonal antibody Keytruda has finally made it to the top of the quarterly PBS reimbursements table.

Keytruda was the top-selling drug globally in 2023, but was held out of first place in Australia by Vertex's cystic fibrosis treatment Trikafta. Despite huge sales in 2023, Trikafta reached an even greater peak in reimbursements in January this year, which saw it cling to the top spot in the first quarter.

To see the whole article, please login


Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.